GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 6 undervalued ...

In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs ...

Pfizer holds 3,458K shares representing 5.03 ... The firm decreased its portfolio allocation in ARVN by 20.78% over the last quarter. Arvinas Background Information (This description is provided ...

Arvinas Inc (NASDAQ:ARVN) aligned with Pfizer to remove two phase 3 combination trials from their joint development plan, potentially limiting future combination therapy options. The company announced ...

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer, and said that it would cut about a third of its workforce.

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first ...

primarily due to changes in total program cost estimates following the removal of certain trials from the development plan with Pfizer (NYSE:PFE). Arvinas emphasized the positive outcomes from its ...